.After elevating $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech hopes to detail on the Nasdaq under the sign "BIOA," depending on to files submitted along with the Stocks and Swap Commission. The company has certainly not openly shared an anticipated monetary quantity for the offering.The clinical-stage firm touts lead candidate azelaprag, a by mouth delivered tiny molecule slated to go into phase 2 testing in combination along with semaglutide-- sold by Novo Nordisk under trademark name Wegovy for fat loss-- in the 1st one-half of upcoming year. Semaglutide is actually additionally offered as Ozempic and also Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is developed to blend effectively along with GLP-1 medicines, boosting weight-loss while preserving muscle mass. The investigational medication was actually discovered to become well-tolerated amongst 265 people across eight phase 1 trials, depending on to BioAge.Recently, BioAge amassed the support of Lilly to operate a test combining azelaprag with the Big Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro and Zepbound for fat burning. The companions are presently carrying out a phase 2 trial of azelaprag as well as tirzepatide, with topline end results assumed in the 3rd quarter of 2025.The biotech is actually additionally considering a blood insulin level of sensitivity proof-of-concept test examining azelaprag as a monotherapy in the very first one-half of following year to sustain potential evidence development. Additionally, the business considers to inquire the FDA for approval in the second half of 2025 to release individual screening for an NLRP3 prevention targeting metabolic illness and also neuroinflammation.BioAge's foreseed transfer to the general public market adheres to a small uptick in planned biotech IPOs coming from Bicara Therapies and Zenas Biopharma. Zooming out, the recent IPO landscape is actually a "mixed picture," along with top notch providers still debuting on the general public markets, only in reduced numbers, according to PitchBook.